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Abstract 
Background: Atrial fibrillation (AF) is reported to be common in patients on maintenance 
dialysis, but estimates of prevalence vary substantially.  To date, no Medicare claims-based 
approach has been employed to rigorously assess prevalence of chronic AF. 
Methods:  A novel database was created to identify patients undergoing maintenance dialysis 
who were dually-eligible for Medicare and Medicaid for at least 3 months in 2004-05.  A 
Medicare claims-based algorithm was used to generate a plausible range of chronic AF 
prevalences using four approaches.  Poisson analysis was employed to determine the 
demographic, functional status, comorbidity, and other factors, as assessed by the Medical 
Evidence Form, associated with chronic AF. 
Results:  Of 102,748 dually-eligible individuals for whom data was complete, 21,540 (21.0%) 
had at least one claim for non-perioperative AF.  Raw percentages (irrespective of length of 
follow-up time) of individuals with chronic AF ranged from 9.8% (using the most inclusive 
strategy) to 4.6% (the most exclusive); intermediate approaches led to closely-clustered 
estimates of 8.1% and 6.4%.  The intermediate approaches demonstrated chronic AF 
prevalence to range from 64.2 (95% confidence intervals, 62.9 – 65.5) to 50.4 (49.2 – 51.7) 
per 1000 patient-years.  Age > 60 years, male sex, Caucasian race, body mass index > 30 
kg/m2, and inability to ambulate were associated with chronic AF; hypertension as a 
comorbidity was inversely associated with AF.  Occurrence of AF was roughly 10 times 
greater in the youngest patients when compared to similar individuals not on dialysis.   
Conclusions:  A linked Medicare-Medicaid database, together with a claims-based diagnostic 
algorithm, was used to generate prevalence estimates for chronic AF in dually-eligible 
dialysis patients.  As expected, AF is far more common than in the non-dialysis population.   
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1 
 Introduction 
 
Atrial fibrillation (AF) is common in end stage renal disease (ESRD) patients on 
maintenance dialysis,1-9 and is independently associated with mortality in the general10 and 
dialysis8, 11 populations.   Recent studies examining the epidemiology of AF in cohorts drawn 
from a large dialysis-provider organization12 and from the Dialysis Outcomes and Practice 
Patterns Study (DOPPS)8 signal renewed interest in this area.   Estimates of AF prevalence 
nevertheless remain quite variable, with rates in the literature having ranged from 6% 1 to 
nearly 27.0% 7, 8 in certain circumstances.  However, estimates provided by many studies are 
not directly comparable, and this relatively wide range is likely to reflect not only differences 
in individual study samples, but also in study design (e.g., prospective cohort vs. retrospective 
cohort vs. cross-sectional studies), classification of AF (e.g., truly chronic versus potentially-
transient), and ascertainment of the diagnosis (e.g., self-reports vs. targeted identification in 
longitudinal cohorts vs. retrospective records review).   Additional work characterizing 
prevalence of chronic AF is therefore needed. 
Development of a billing claims-based algorithm would provide additional 
opportunities for the study of AF.  Such a validated algorithm has already proven extremely 
useful in non-dialysis patients with AF13, 14, and use of a suitably-adapted algorithm in 
maintenance dialysis patients could allow a more far-reaching identification of dialysis 
patients with chronic AF.  If combined with information on longitudinal medication 
exposures, studies of drug exposure-outcome relationships in dialysis patients with chronic 
AF could be undertaken in future. 
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In this investigation, we constructed a novel linked Medicare-Medicaid database to 
determine prevalence of chronic AF in a large sample of maintenance dialysis patients.  Using 
claims data provided by the United States Renal Data Service (USRDS), which incorporates 
Medicare data on dialysis patients, as well as 50-state Medicaid data, which permits 
ascertainment of filled prescription mediations, we identified dually-eligible (Medicare-
Medicaid) chronic dialysis patients in 2004-05.  We then employed a rigorous claims-based 
algorithm, originally developed for identifying chronic AF in the general population13, 14, to 
ascertain a range of plausible chronic AF prevalences in dialysis patients under various 
assumptions.  Our aims were to provide a comprehensive examination of the prevalence of 
chronic AF in dually-eligible chronic U.S. dialysis patients, and to determine clinical and 
demographic factors associated with this disorder in a large cohort of dialysis patients. 
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Methods 
 
Study design 
 A retrospective cohort analysis of patients undergoing maintenance dialysis between 
January 1, 2004 and December 31, 2005 was utilized to identify persons with chronic AF; 
details are described below.  The prevalence of risk factors for chronic AF were based on a 
cross-sectional analysis of those patients who were observable for at least 3 months during the 
2-year window, after having initially survived their first 90 days on dialysis (thereby 
permitting inclusion in the USRDS). 
 
Data sources for analysis 
We utilized we data from three primary sources, the Centers for Medicare and 
Medicaid Services (CMS) Medicaid Analytic eXtract (MAX) files, Medicare Institutional and 
Physician/Supplier Claims files, and the USRDS.  The USRDS tracks dialysis patients from 
initiation of dialysis through transplantation or death, and extracts Medicare data for end stage 
renal disease (ESRD) patients enrolled in Medicare (comprising ≈ 98% of prevalent dialysis 
patients).  USRDS data includes, from Medicare, the Institutional (“Part A”) and 
Physician/Supplier (“Part B”) Claims files.  From CMS, the MAX Personal Summary (PS) 
files and final action prescription drug claim (Rx) files for calendar years 2004-05 were 
obtained.  To link these sources, we created, from the MAX PS files, a record listing of 
unique Medicaid-eligible persons for all 50 states and D.C. based upon social security number 
(SSN), date of birth, gender, and state.  For each unique record, we then created our own 
unique ID (“KUMC_ID”).  This list was sent to the USRDS, which performed a series of 
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deterministic matches against the USRDS core files.  The USRDS removed SSNs and health 
insurance claim numbers (HICs), providing a crosswalk file that joined the USRDS_ID to the 
KUMC_ID.  The USRDS_ID and KUMC_ID were thereby linked, enabling unique 
individuals to be identified.  The KUMC_ID and USRDS_IDs were then linked to the 
appropriate MSIS_IDs within the MAX PS files, enabling further linkage (via the MSIS_ID) 
between the MAX PS and Rx files.  We then replaced the MSIS_IDs with the USRDS_IDs, 
so that complete linkage was possible across Medicare Parts A & B claims (previously 
provided by the USRDS) and the Medicaid PS & Rx files. 
To acquire requisite information on individual persons in the USRDS, the USRDS 
Core compact disk (CD) was used.  Data contained in the Core CD is generated upon 
initiation of dialysis, when providers are required to submit to CMS the Medical Evidence 
Form (CMS 2728) documenting patient demographic characteristics, comorbid conditions, 
laboratory values prior to the first dialysis treatment, date of dialysis initiation, and dialysis 
modality and setting.  Over time, changes in patient residence, payer status, and treatment 
history, as well as information on transplantation and death, are submitted to CMS and 
subsequently incorporated into the Core CD.   
 
Study cohort and rationale for analytic approach 
We identified unique individuals over the age of 20 years who survived > 90 initial 
days on dialysis, who were Medicare-eligible for at least 90 days, and who were 
simultaneously enrolled in Medicaid and Medicare programs for at least 90 days during 
period the 2-year observation window.  Medicare enrollment was verified using the USRDS 
PAYHIST files, while Medicaid eligibility was determined from the MAX PS files.  We 
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excluded persons who initiated HD prior to 1/1/1980, who were enrolled in the Veterans 
Administration healthcare system or in Medicaid managed care, and those who received a 
transplant prior to 1/1/2004.  (Of note, persons with ESRD were not eligible for Medicare 
managed care plans prior to 2006.)  We considered only the first period of dual eligibility 
(i.e., we censored at the first loss of dual eligibility). 
  
Determination of chronic atrial fibrillation 
 We employed several rigorous algorithms adapted from one used by other 
investigators in order to determine the presence of chronic AF.  The International 
Classification of Diseases (ICD-9) code 427.31 was used to identify AF13.  To decrease the 
potential sources for misclassification attributable to transient, postoperative, valvular, or 
secondary sources of AF, exclusions were made using a method adapted from Go et al13, 14.  
Specifically, we eliminated patients with evidence of valvular heart disease (from ICD-9 
codes) and hyperthyroidism or thyrotoxicosis; exclusions for thyroid disorders were made 
based on the presence of relevant ICD-9 and/or CPT (Common Procedural Technology) 
and/or HCPCS (Healthcare Common Procedure Coding System) codes as well as 
prescriptions for propothiouracil or methimazole (identified from the MAX Rx files).  In the 
case of potential perioperative sources of AF (e.g., coronary artery bypass surgery), claims 
(rather than individuals) were eliminated unless there was a preexisting (> 30 d) AF claim, 
and AF status determined as per the algorithm used for other individuals (described below).  
A full accounting of this exclusionary strategy listed in Supplementary Table 1. 
To classify individuals as having chronic AF, we used a total of 4 algorithms, 
representing a spectrum of “liberal” to “conservative” approaches, in order to generate a range 
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of plausible prevalence estimates.   One cardinal approach utilized a total of 2 (or more) AF 
claims, at least 1 of which was an outpatient claim, and which had to be separated by 30 or 
more days.  A second approach utilized a total of 3 (or more) AF claims (at least 2 of which 
were outpatient), in which each was separated by at least 30 days.  To each of these two basic 
approaches, we added an additional element by establishing criteria for an “episode of care” 
window.  Since outpatient AF claims related to a (subsequent) inpatient admission for AF 
could, conceivably, occur in the few days immediately prior to the hospital admission, we 
expunged all outpatient AF claims within 7 days of an AF claim-containing admission.  
Similarly, since outpatient followup care for AF could be closely tied to a recent hospital 
admission for AF, we expunged all outpatient AF claims within 30 days after an AF claim-
containing admission.  By establishing the 7-day pre- and 30-day post-admission windows, 
AF claims likely to be associated with a single episode of care were eliminated.  Our 4 
approaches therefore consisted of a 2 x 2 matrix of claim number (2 claims versus 3) by 
episode-of-care window imposition (no window versus imposition of the 7 day-pre / 30 day-
post window).   Finally, to qualitatively compare or results to the larger dialysis population, 
we performed one additional analysis in which the full Medicare population (irrespective of 
Medicaid eligibility) was investigated, using the 2-claim approach with the episode-of-care 
window invoked. 
  
Exposure to drugs used in the treatment of hyperthyroidism 
 Individuals who ever had a prescription for methimazole or propothiouracil were 
eliminated.  MAX prescription drug claims included the national drug code (NDC) for these 
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drugs13, 14.  We matched drug name and therapeutic class information in the drug claims at the 
level of the NDC code using Multum Lexicon (Cerner Corporation, Kansas City, KS).   
 
Variables for analysis 
A variety of covariates, as recorded on the CMS 2728 form at time of dialysis 
initiation, were considered for analysis.  Demographic variables were age, sex, and race by 
ethnicity (four mutually-exclusive groups consisting of non-Hispanic Caucasian, non-
Hispanic African-American, Hispanic, and Other).  Body mass index (BMI) was classified 
into 4 categories; < 20 kg/ m2, 20-24.99 kg/m2, 25-29.99 kg/m2, ≥ 30 kg/m2.  Risk behavior 
factors examined were smoking and substance abuse (alcohol or illicit drugs), and functional 
status markers were employment, inability to ambulate, and inability to transfer.  Major 
comorbidities were considered to be diabetes (types I and II combined), hypertension, 
congestive heart failure, coronary artery disease, cerebrovascular disease, peripheral vascular 
disease, and cardiac dysrhythmia.  Since the CMS 2728 form is structured such that diseases 
like diabetes or hypertension may be considered as both a cause of ESRD and/or a 
comorbidity, diabetes and hypertension were considered present in an individual if they were 
listed as either the cause of ESRD or as a comorbidity15.  Modality upon initiation of dialysis 
was categorized as in-center hemodialysis (HD) or self-care dialysis (home HD or peritoneal 
dialysis (PD)) based upon the dialysis modality history contained in the USRDS database.  
The sole laboratory value analyzed was hemoglobin at baseline, with a dichotomized level at 
11g/dL.   Serums albumin was not analyzed, since ~ 20% of individuals did not have this 
value recorded.  
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Statistical analyses: overall and specific approaches 
We generated descriptive statistics (means for continuous variables and percentages 
for categorical variables) for the patients with and without chronic AF.  To explore the 
differences between two groups (that is, those with and without chronic AF), we performed 
unconditional logistic regression for the bivariate analyses.  Raw percentages of individuals 
who ever satisfied the definition of chronic AF (irrespective of length of followup time) were 
generated for each of the approaches.  We then performed Poisson analysis in which the 
number of individuals with AF constituted the numerator and person-time of followup 
constituted the denominator; performance of the model was assessed by examination of 
residual plots.  Age was dichotomized at 60 years to improve fit of the model.  Adjusted 
prevalence rate ratios (APRRs) for AF were generated for each covariate. 
Due to the large size of the study population, we attempt to distinguish between 
findings that were only statistically significant from those that are more likely to be clinically 
meaningful.  Thus a P -value of < 0.01 was considered the threshold for statistical 
significance.  All statistical analyses were done with SAS 9.1 (Cary, NC, USA).   
 
Compliance and protection of human research participants 
The research protocol was approved by the institutional review board at the University 
of Kansas Medical Center (KUMC), and the project was undertaken according to the 
principles of the Declaration of Helsinki.  Data Use Agreements (DUA) between KUMC and 
the USRDS and CMS permitted the data linking across the USRDS, Medicare and Medicaid 
files.  In accordance with our DUA, social security numbers and other identifying information 
were removed from the linked files provided by CMS and the USRDS. 
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Results 
 
 A total of 430,227 individuals on chronic dialysis were identified in the Core CDs 
from 2004 and 2005.  Of these, 125,668 were dually-eligible (without managed care) for at 
least 90 days.  Figure 1 demonstrates construction of the cohort.  A small number of persons 
(n = 462) were excluded due to hyperthyroidism, while a larger number (n = 8384) were 
eliminated with evidence of valvular heart disease, leaving 116,858 persons.  We then 
eliminated individuals with incomplete data, which left 102,748; the vast majority of attrition 
occurred because information on BMI and/or hemoglobin level was missing.  Individuals with 
any claims for AF then numbered 21,780, but after eliminating claims within 30 days after a 
cardiac operation, 240 individuals were removed, leaving 21,540.  This constitutes the initial 
numerator.  Thus, 21.0% of persons had at least one claim for AF.   
 Supplementary Table 2 shows the distribution of inpatient (IP) and outpatient (OP) 
claims.  Among the 85.9% who had no IP claims, 79.0% had no OP claims, 3.7% one OP, 
1.1% two OP, and 2.0% three or more OP claims.  Of the 14.1% who had at least one IP 
claim, 2.0% had no OP claims, 1.5% one OP claim, 1.3% two OP claims, and 9.3% three or 
more OP claims. 
Raw percentage estimates (that is, irrespective of length of followup) of persons with 
chronic AF were generated, as shown in Table 1.  The most liberal approach (total of 2 or 
more claims, at least 1 of which was OP) yielded 9.8%, while the most conservative (3 or 
more claims, at least 2 of which were OP, with the episode-of-care window restriction) 
yielded 4.6%, a difference of roughly 2-fold.  However, the intermediate approaches led to 
more closely-clustered estimates of 8.1% and 6.4%, difference of about 1.3-fold. 
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Table 2 illustrates the bivariate analysis of the difference between patients with and 
without chronic AF of the characteristics upon initiation of dialysis of the; the 2-claim + 
episode-of-care window was used.    The total cohort consisted of 102,748 individuals.  Mean 
age was 59.4 ± 15.5 years and 52.6% were female, while 33.3% were Caucasian and 44.5% 
African-American.  Fully 58.4% were diabetics.   
Of this cohort, 8347, or 8.1%, had chronic AF.  Patients with AF were significantly (P 
< 0.01) more likely to be older (69.6 versus 58.6 years), female, Caucasian, have a higher 
BMI, be non-smokers and non-substance abusers, be unemployed, be unable to ambulate and 
transfer, and have diabetes (DM), congestive heart failure (CHF), coronary artery disease 
(CAD), peripheral vascular disease (PVD), and a history of a cerebrovascular accident 
(CVA).  Patients with AF were also more likely to be on in-center hemodialysis and have a 
hemoglobin (Hb) level < 11.0 g/dL.  Only in the case of hypertension was the difference 
between persons with and without chronic AF less striking (P = 0 .006), albeit still significant 
by our definition. 
An analysis using the next-most conservative approach, namely the requirement of 3 
or more claims but without the imposition of the episode-of-care window, yielded virtually 
identical results (not shown).  The sole difference in the bivariate analysis using this approach 
was that hypertension was clearly no different between individuals with and without AF (P = 
0.15); all other previous associations remained significant. 
Table 3 illustrates the result of Poisson regression modeling of the 2-claim, episode-of 
care approach.  Age > 60 yr, male sex, Caucasian race, BMI > 30 kg/m2, lack of smoking, 
unemployed status, inability to ambulate, HTN as the cause of ESRD, and histories of CAD, 
and CHF were significantly (P < 0.01) associated with chronic AF; history of CVA was 
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nearly significant (P = 0.011).  Lack of hypertension, considered as a comorbidity, was also 
associated with chronic AF.  Specifically, the APRR of 0.82 indicates that, among those 
individuals in whom HTN was not the primary cause of ESRD, there was a lesser prevalence 
of chronic AF relative to those who did not have HTN as a comorbidity or a cause of ESRD.  
Notably, DM, use of self-care dialysis, and Hb < 11 g/dL were not associated with AF.  
Nearly-identical results were obtained in an analysis using the 3-claim approach without the 
episode-of-care window invoked (not shown), with the only difference being that employment 
status was no longer as significantly associated with AF (P = 0.013). 
To determine whether our analysis in dually-eligible patients was extrapolatable to the 
larger body of chronic dialysis patients, we ran a comparable analysis, using the 2-claim + 
episode-of-care approach, in the entire group of Medicare dialysis patients (i.e., irrespective 
of Medicaid eligibility).  After all exclusions, there were 254,230 persons with complete data 
to study, with 61,782 having at least one AF claim, representing 24.3% of all individuals.  The 
distribution pattern of claims originally depicted in Supplementary Table 1 was very similar 
in the entire group, with the only striking difference being that, in patients with at least 1 IP 
claim, 11.7% (versus 9.3% previously) had 3 or more OP claims.  The overall raw percentage 
of individuals was higher, at 11.2%, compared to the 8.1% of the comparable approach in 
dually-eligible patients.  However, mean age of the patients in this group was much higher 
than in the dually-eligible group (63.3 versus 59.4 years, respectively).  Poisson modeling in 
this group yielded generally similar results; all previously-identified associations remained 
intact, but inability to transfer, history of CVA, and use of in-center hemodialysis now 
became significant.  A lack of hypertension as a comorbidity was once again associated with 
chronic AF. 
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Formal prevalence estimates were generated from the Poisson model.  For the dually-
eligible patients using the 2-claim + episode-of-care window approach, the rate was 64.2 
(95% confidence intervals, 62.9 – 65.6) per 1000 person-years; for the 3-claim approach 
without the episode-of-care window, the rate was 50.4 (49.2 – 51.7) per 1000 person-years.  
In the older Medicare population, the rate (again using the 2-claim + episode-of-care window 
approach), the rate was 82.2 (81.3 – 83.2) per 1000 person-years. 
Finally, to facilitate comparison with data in the general population, we calculated raw 
percentages of chronic AF by age, stratified by decade and sex, using the 2-claim + episode-
of-care window approach.  Table 4 displays these percentages.  As expected, our estimate is 
higher than that of the general population and was evident across age strata.  In males, 
absolute rates were roughly 2-fold (in the oldest individuals) to 10-fold (in the youngest) 
higher in dialysis patients than in non-dialysis patients14.  In young individuals aged 30- <40, 
rates were fully 2.0% in females and 2.9% in males; in individuals aged 80-<90, rates were 
17.6% in females and 18.3% in males.  These findings demonstrate that chronic AF both 
occurs at a younger age in the dialysis patients and has sustained high prevalence rates in the 
elderly.   
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Discussion 
 
In this study, we adapted a well-established Medicare claims-based algorithm for the 
identification of patients with chronic AF to the dually-eligible dialysis population.  Our study 
compliments and expands upon other reports by demonstrating an approach through which 
claims data can be utilized for AF identification in dialysis patients, and by establishing a 
range of plausible prevalence estimates for this disorder.  Since we believe it likely that our 
most liberal and conservative approaches overestimate and underestimate, respectively, 
prevalence of chronic AF, we suggest that the true prevalence likely lies between 50.4 and 
64.2 per 1000 patient-years (between 6.4 and 8.1% in raw percentages), at least in dually-
eligible U.S. dialysis patients.  Since the general Medicare dialysis population is older than 
that with Medicaid, prevalence in the former is probably about 1.4 times higher.  An 
additional contribution of the present report is quantification of the strong associations 
between chronic AF prevalence and a variety of demographic, anthropometric, risk behavior, 
functional status, comorbidity, dialysis modality, and laboratory-value factors as recorded 
upon dialysis initiation. 
Given recent renewed interest in AF in dialysis patients8, 9, 12, 16, the ability to identify 
such individuals using claims data provides a more universal platform for further 
investigation.  This approach does not require utilization of more access-limited databases, 
such as those of large dialysis-provider organizations or of longitudinal epidemiological 
studies (e.g., DOPPS).  Fortunately, a template for a claims-based algorithm for identification 
of AF exists, having been validated and published in a variety of widely-disseminated 
reports13, 14.  However, we thought that some modification of the original approach was 
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warranted, principally because dialysis patients utilize vastly greater healthcare resources, 
and, as a result, come into contact with the healthcare system far more often than do 
ambulatory patients with less prodigious comorbidity burdens17.  We thus reasoned that 
imposing a restriction requiring an additional (i.e., 3rd) AF claim might result in less 
misclassification and would prove informative for one approach.  Additionally, our overall 
strategy was informed by manual inspection of the claim patterns in several hundred patient 
records, which made it clear from a clinical perspective that some “outpatient” AF claims 
were almost certainly immediately associated with a proximate AF-related hospital admission.  
Therefore, establishment of an episode-of-care window paradigm, to minimize 
misclassification of acute as chronic AF, also seemed like a useful complementary approach.  
Fortunately, our two “intermediate” approaches (i.e., neither the most liberal nor the most 
conservative) led to prevalence estimates that were relatively close. 
Our raw prevalence estimates appear to be somewhat lower than some6-8, but not all12, 
previous reports, but true prevalence comparisons may not be possible because we calculated 
events in person-time units using a Poisson analysis; most reports do not formally report rates 
as such.  In terms of raw percentages, the DOPPS investigators recently reported a prevalence 
rate of 11.3% to 24.7% in Western countries, with the rate in the U.S. precisely reflecting the 
overall rate of 12.5% 8.  However, once we empirically inspected the individual patterns of 
AF claims in several hundred patients in a variety of scenarios, many of previously-reported 
estimates seemed implausibly high to us.  Recent work from a small but in-depth study of 256 
patients revealed a lower-than-traditional estimate of 7.4% in incident dialysis patients, as 
well as overall rates of AF about 60% higher (12.1%)11, suggesting that a substantial 
proportion of individuals labeled as having AF are likely to have transient AF or AF due to 
15 
secondary causes.  Thus high AF rates reported in other studies may be because individuals 
with secondary causes of AF or transient AF are being captured, and perhaps misclassified, by 
their respective identification strategies.  Additional evidence for lower AF rates comes from 
a recent report by Chan et al, who concluded that AF rates were “only” 4.5% in incident 
dialysis patients12.  It seems likely that rates would become higher in dialysis populations 
consisting of more “prevalent” individuals, since increasing age, a concomitant growing 
comorbidity burden, and increased exposure to the hemodialysis procedure itself (a 
physiologic stress test, given the need for rapid ultrafiltration) might be expected to result in 
increased rates of AF. 
Our findings contribute to the understanding of the epidemiology of AF in part 
because the present study is larger than other studies by roughly an order of magnitude.  As 
such, previously-reported findings of associations between various patient factors, at least 
those identified upon dialysis initiation, and chronic AF can be robustly quantified.  As 
expected, we echoed the finding of the association of age with AF reported by Wizemann et al 
in the DOPPS database8, Abbott et al (in a univariate analysis) in Dialysis Morbidity and 
Mortality (DMMS) Wave II study18, Vasquez et al in their small but well-studied incident 
dialysis cohort11, and others5, 7.  Both Abbott et al and Wizemann et al also found Caucasian 
race to be associated with AF8, 18.  The DOPPS investigators also found BMI to be 
significantly correlated in direct fashion with preexisting AF8.  Notably, the role of sex in 
dialysis patients with AF remains unclear; while some investigators report sex to be 
unassociated with either incident or prevalent AF5, 7, 8, and others that female sex is the risk 
factor11, our finding of an association of male sex with chronic AF is reflective of findings in 
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the general population14.  As anticipated, CAD and CHF emerged as comorbidity factors 
associated with AF in our study. 
One interesting finding was an inverse association, after adjustment for other factors, 
between hypertension, considered as a comorbidity, and chronic AF in our study.  Among 
individuals without HTN as their primary cause of ESRD, AF was less common in 
individuals with HTN as a comorbidity than in those without.  While HTN is a risk factor for 
AF in the general population19-24, in ESRD, studies of prevalent dialysis patients may be 
characterized by a distinct physiology, namely the controversially-termed phenomenon of 
“reverse epidemiology”25, 26.  Evidence from the DOPPS database appears to support our 
results: while a formal diagnosis of hypertension was not associated with AF, low pre-dialysis 
systolic blood pressure was8, lending plausibility to the hypothesis that when dialysis patients 
manifest AF, many of them are experiencing decreased cardiac output and concomitant 
hypotension.  Since AF may contribute to hypotension in dialysis patients, this might be an 
explanation for our findings.   
Our study has several important limitations.  First, we did not have access to medical 
charts.  However, we adapted a well-established validated algorithm with the express goal of 
minimizing the possibility that secondary, transient, or postoperative causes of AF would be 
misclassified as truly chronic AF.  We then performed a series of increasingly-conservative 
approaches to yield an overall range of plausible prevalence estimates.  Second, we used the 
CMS 2728 form to identify comorbidities,as is widely done15, 27-32.  Although this form has 
several strengths, a more rigorous, but far more complex, approach would be to use a claims-
based approach to identify comorbidities.  Such an approach exists33, 34, and should be a 
subject of future investigations, but it does require a minimum survival of 9 months and is 
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therefore could introduce an immortal time bias35; any conclusions drawn from such an 
approach would have to be considered accordingly.  Finally, our primary analysis was 
confined to dually-eligible individuals.  Since individuals with Medicaid are likely to be the 
most medically-needy and to have more comorbidities at a younger age than the non-dually-
eligible population36, our results can only be generalized with caution.  However, we 
performed an additional analysis in the general Medicare population, and found a consistent 
estimate once the increased age of non-Medicaid individuals is considered.   
In conclusion, we used a Medicare claims-based approach to define the prevalence of 
chronic AF in a large number of dually-eligible maintenance dialysis patients.  This approach 
is likely to prove suitable for future investigations using Medicare and Medicaid data.  Our 
prevalence estimate is somewhat lower than that of many reports, which is probably due to 
the rigor of our strategy for identifying chronic AF.  Even so, the prevalence rates we report 
are still far higher than in the non-dialysis population.  The important factors and 
comorbidities associated with chronic AF generate hypotheses suitable for future study.  
Investigations of many aspects of chronic AF in dialysis patients, such as further 
examinations of the patterns of warfarin use and the risks and benefits of this therapy, should 
be undertaken.    
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Figure 1.  Exclusion flowchart demonstrating the creation of the cohort of individuals without 
claims for atrial fibrillation (“denominator”) and with at least one non-perioperative claim for 
atrial fibrillation (“numerator”) for 2004-05. 
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1. 
 Dually-eligible for Medicare and Medicaid (without managed care) for ≥ 90 days 
 
N = 125, 668 
Excluded* due  to hyperthyroidism (ICD-9, CPT, Medicaid Rx records): N = 462 
Excluded* due to valvular heart disease: N = 8384 
 
N = 116,858 remaining 
Excluded due to incomplete data: N = 14,110 
 
N = 102,748 remaining 
(“denominator”) 
Individuals with at least one claim for AF 
 
N = 21,780 remaining 
Excluded due to claims being related to cardiac surgery: N = 240 
 
N = 21,540 remaining 
(“numerator” of individuals with at least 1 claim for non-perioperative AF) 
*Some individuals excluded due to both hyperthyroidism and valvular heart disease. 
ICD-9, International Classification of Diseases-9; CPT, Common Procedural 
Terminology; HCPCS, Healthcare Common Procedural Coding System; Rx, 
prescription; AF, atrial fibrillation. 
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Table 1.  Sources of exclusion of individuals with potential secondary sources of atrial 
fibrillation. 
 
Variable Source Exclusion Level Time Period 
Coronary bypass surgery ICD-9 36.10-.19 claim within 30 days of AF 
Cardiac surgery/   
   procedure 
ICD-9 35.31-.39, .41-
.42, .50-.54, .60-.63, .70-
.73, 37.24-.25, .35 
claim within 30 d 
Valvular repair ICD-9 35.01-.02, .11-
.12, .21-.24 
claim within 30 d 
Valvular heart disease ICD-9 394.0, .2, 396.0-
.1, .8, 746.5, V42.2, 
V43.3 
person ever 
Pericardial surgery ICD-9 37.10-.12, .31-
.33, .40 
claim within 30 d 
Hyperthyroidism/ 
   thyrotoxicosis 
ICD-9 242.0-.9; CPT 
2420-24, 2428-29; 
HCPCS 79000-1, 79005; 
propylthiouracil or 
methimazole 
person ever 
ICD-9, International Classification of Diseases-9; AF, atrial fibrillation; CPT, Common 
Procedural Technology; HCPCS, Healthcare Common Procedure Coding System 
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Table 2.  Percentage distribution of outpatient and inpatient claims for atrial fibrillation  
in dually-eligible chronic dialysis patients, 2004-05. 
 
 0 Outpatient 1 Outpatient 2 Outpatient 3+ Outpatient Total 
0 Inpatient,% 79.0 3.7 1.1 2.0 85.9 
1+ Inpatient, % 2.0 1.5 1.3 9.3 14.1 
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Table 3.  Percentage of individuals with chronic atrial  
fibrillation, according to the four definitions. 
 
Identification strategy % with AF 
2+ claims 9.8 
2+ claims with episode-of-care window 8.1 
3+ claims 6.4 
3+ claims with episode-of-care window 4.6 
In the case of individuals with 2 claims, no more than 1  
could be an inpatient claim.  In the case of individuals  
with 3 claims, no more than 1 could be an inpatient claim.   
“Episode of care window” defined in text.  AF, chronic  
atrial fibrillation 
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Table 4.  Characteristics of dialysis patients with and without chronic atrial fibrillation. 
 
 
Characteristic 
Total  
(n =102748) 
AF  
(n = 8347) 
non-AF  
(n = 94401) 
 
P -value 
Age, years 59.4 ± 15.5 69.6 ± 11.5 58.6 ± 15.4 < 0.0001 
Female sex, n (%) 54016 (52.6) 4717 (56.5) 49299 (52.2) < 0.0001 
Race/Ethnicity, n (%)    < 0.0001 
   African-American 45751 (44.5) 2646 (31.7) 43105 (45.7)  
   Caucasian 34258 (33.3) 4209 (50.4) 30049 (31.8)  
   Hispanic 16443 (16.0) 967 (11.6) 15476 (16.4)  
   Other 6296 (6.1) 525 (6.3) 5771 (6.1)  
BMI category, n (%)    < 0.0001 
   < 20 kg/m2 9819 (9.6) 699 (8.4) 9120 (9.7)  
   20-24.9 kg/m2 29805 (29.0) 2223 (26.6) 27582 (29.2)  
   25-29.9 kg/m2 27952 (27.2) 2290 (27.4) 25662 (27.2)  
   30+ kg/m2 35172 (34.2) 3135 (37.6) 32037 (33.9)  
Smoker, n (%) 6819 (6.6) 382 (4.6) 6437 (6.8) < 0.0001 
Substance abuser, n 
(%) 
3345 (3.3) 140 (1.7) 3205 (3.4) < 0.0001 
Unemployed, n (%) 96290 (93.7) 8106 (97.1) 88184 (93.4) < 0.0001 
Inability to ambulate, 
n (%) 
4226 (4.1) 563 (6.7) 3663 (3.9) < 0.0001 
Inability to transfer, n 
 
1487 (1.4) 227 (2.7) 1260 (1.3) < 0.0001 
Primary cause of 
ESRD, n (%) 
   < 0.0001 
   Diabetes 50670 (49.3) 4199 (50.3) 46471 (49.2)  
   Hypertension 27805 (27.1) 2381 (28.5) 25424 (26.9)  
   Glomerulonephritis 9892 (9.6) 539 (6.5) 9353 (9.9)  
   Other 14381 (14.0) 1228 (14.7) 13153 (13.9)  
Comorbidities, n (%)     
   Hypertension 87705 (85.4) 7039 (84.3) 80666 (85.5) 0.006 
   Diabetes 59973 (58.4) 5138 (61.6) 54835 (58.1) < 0.0001 
   CHF 29718 (28.9) 3715 (44.5) 26003 (27.5) < 0.0001 
   CAD 20630 (20.1) 2819 (33.8) 17811 (18.9) < 0.0001 
   PVD 12139 (11.8) 1419 (17.0) 10720 (11.4) < 0.0001 
   CVA 9100 (8.9) 1023 (12.3) 8077 (8.6) < 0.0001 
Self-care dialysis, n 
(%) 
5742 (5.6) 364 (4.4) 5378 (5.7) < 0.0001 
Hb < 11.0 g/dL, n 
(%) 
79061 (76.9) 6271 (75.1) 72790 (77.1) < 0.0001 
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AF, chronic atrial fibrillation; BMI, body mass index; ESRD, end stage renal disease;  
CHF, congestive heart failure; CAD, coronary artery disease; PVD, peripheral arterial 
disease; CVA, cerebrovascular accident; HD, hemodialysis; Hb, hemoglobin 
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Table 5.  Adjusted prevalence rate ratio estimates for dialysis patients  
with chronic atrial fibrillation. 
 
Characteristic APRR 95% CIs P -value 
Age > 60 y 3.37 3.18 – 3.57 < 0.0001 
Male Sex 1.12 1.08 – 1.18 < 0.0001 
Race/Ethnicity    
   Caucasian – – – 
   African-American 0.50 0.48 – 0.53 < 0.0001 
   Hispanic 0.45 0.42 – 0.49 < 0.0001 
   Other 0.64 0.59 – 0.71 < 0.0001 
BMI category    
   20-24.9 kg/m2 – – – 
   < 20 kg/m2 0.98 0.90 – 1.07 0.69 
   25-29.9 kg/m2 1.06 1.01 – 1.13 0.043 
   30+ kg/m2 1.22 1.16 – 1.29 < 0.0001 
Smoker, n (%) 0.80 0.72 – 0.89 < 0.0001 
Substance abuser, n (%) 0.88 0.74 – 1.05 0.15 
Employed 0.80 0.70 – 0.91 0.0009 
Inability to ambulate 1.19 1.07 – 1.32 0.0015 
Inability to transfer 1.21 1.03 – 1.43 0.020 
Comorbidities    
   Hypertension 0.82 0.77 – 0.87 < 0.0001 
   Diabetes 1.01 0.94 – 1.09 0.82 
   CAD 1.29 1.22 – 1.35 < 0.0001 
   CHF 1.53 1.46 – 1.60 < 0.0001 
   CVA 1.09 1.02 – 1.17 0.011 
   PVD 1.02 0.96 – 1.08 0.54 
Cause of ESRD    
   Diabetes – – – 
   Hypertension 1.30 1.21 – 1.41 < 0.0001 
   Glomerulonephritis 1.08 0.97 – 1.21 0.17 
   Other 1.14 1.04 – 1.24 0.0039 
Self-care dialysis 0.94 0.85 – 1.05 0.29 
Hb < 11.0 g/dL 0.98 0.94 – 1.03 0.53 
APRR, adjusted prevalence ratio ratio; CI, confidence interval; BMI,  
body mass index; ESRD, end stage renal disease; CHF, congestive heart  
failure; CAD, coronary artery disease; PVD, peripheral arterial disease;  
CVA, cerebrovascular accident; HD, hemodialysis; Hb, hemoglobin 
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Table 6.  Percentage of individuals identified  
as having chronic atrial fibrillation, by age  
decade and sex. 
 
Age decade F with AF,% M with AF,% 
20-29.9 0.6 0.8 
30-39.9 1.2 1.4 
40-49.9 2.0 2.9 
50-59.9 5.0 5.3 
60-69.9 8.7 9.7 
70-79.9 14.2 15.5 
80-89.9 17.6 18.3 
90+ 18.3 19.7 
AF, chronic atrial fibrillation 
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